Mark D. Pegram

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

T. Fleming, L. Norton, J. Baselga, 2001, The New England journal of medicine.

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer

L. Koniaris, M. Jordá, J. Slingerland, 2012, Breast Cancer Research and Treatment.